Case report
Open access
Sep 2026
Case Report: Reopening the anabolic window — romosozumab added to ongoing denosumab for severe osteoporosis in two kidney transplant recipients
Kidney transplant recipients develop disorders of mineral and bone metabolism that further impair bone strength, leading to osteoporosis and a high fracture risk. However, evidence in this setting is limited. Romosozumab, a sclerostin inhibitor with both anabolic and antiresorptive effects, is an attractive option, but...
Simona Barbuto, Paolo Mastromauro, G. Zavatta et al.
· Frontiers in Endocrinology · 0 citations